ProCE Banner Activity

Frequently Asked Questions About Advances in the Management of Hemophilia A

Clinical Thought
What is the role of pharmacokinetic testing? What is the best option for previously untreated patients? Here’s our take.

Released: January 30, 2020

Expiration: January 28, 2021

No longer available for credit.

Share

Faculty

Michael Callaghan

Michael Callaghan, MD

Associate Professor
Department of Hematology
Wayne State University
Hematologist
Division of Hematology/Oncology
Childrens Hospital of Michigan
Detroit, Michigan

Stacy E. Croteau

Stacy E. Croteau, MD, MMS

Assistant Professor of Pediatrics
Department of Hematology
Boston Childrens Hospital
Harvard Medical School
Boston, Massachusetts

Cindy A. Leissinger

Cindy A. Leissinger, MD

Director
Louisiana Center for Bleeding and Clotting Disorders
New Orleans, Louisiana

Guy Young

Guy Young, MD

Director, Hemostasis and Thrombosis Center
Director, Clinical Coagulation Laboratory
Cancer and Blood Disorders Institute
Children's Hospital Los Angeles
Professor of Pediatrics
Division of Hematology/Oncology
Department of Pediatrics
University of Southern California Keck School of Medicine
Los Angeles, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Genentech TEXT Only

Faculty Disclosure

Primary Author

Michael Callaghan, MD

Associate Professor
Department of Hematology
Wayne State University
Hematologist
Division of Hematology/Oncology
Childrens Hospital of Michigan
Detroit, Michigan

Michael Callaghan, MD, has disclosed that he has received consulting fees from Bioverativ, Pfizer, Roche/Genentech, and Shire and has ownership interest in Alnylam.

Stacy E. Croteau, MD, MMS

Assistant Professor of Pediatrics
Department of Hematology
Boston Childrens Hospital
Harvard Medical School
Boston, Massachusetts

Stacy E. Croteau, MD, MMS, has disclosed that she has received consulting fees from Bayer, Biomarin, Bioverativ, Catalyst Biosciences, CSL-Behring, Genentech, Novo Nordisk, and Octapharma and funds for research support from Boehringer Ingelheim, Genentech, Octapharma, Pfizer, and Spark.

Cindy A. Leissinger, MD

Director
Louisiana Center for Bleeding and Clotting Disorders
New Orleans, Louisiana

Cindy A. Leissinger, MD, has disclosed that she has received consulting fees from Bayer, CSL Behring, Kedrion, Genentech/Roche, Spark, Takeda, and UniQure and funds for research support from Genentech/Roche.

Guy Young, MD

Director, Hemostasis and Thrombosis Center
Director, Clinical Coagulation Laboratory
Cancer and Blood Disorders Institute
Children's Hospital Los Angeles
Professor of Pediatrics
Division of Hematology/Oncology
Department of Pediatrics
University of Southern California Keck School of Medicine
Los Angeles, California

Guy A. Young, MD, has disclosed that he has received consulting fees from CSL Behring, Freeline, Genentech/Roche, Grifols, Kedrion, Novo Nordisk, Shire/Takeda, Spark, and uniQure; fees for non-CME/CE services from Bioverativ and Genentech; and funds for research support from Genentech.